Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 42 studies | 50% ± 21% | |
fibroblast | 39 studies | 40% ± 20% | |
endothelial cell | 27 studies | 31% ± 12% | |
smooth muscle cell | 24 studies | 27% ± 10% | |
non-classical monocyte | 22 studies | 42% ± 12% | |
pericyte | 21 studies | 31% ± 12% | |
endothelial cell of lymphatic vessel | 19 studies | 36% ± 12% | |
myeloid cell | 14 studies | 41% ± 16% | |
myofibroblast cell | 12 studies | 28% ± 11% | |
monocyte | 11 studies | 37% ± 18% | |
classical monocyte | 11 studies | 37% ± 20% | |
connective tissue cell | 11 studies | 34% ± 13% | |
ciliated cell | 10 studies | 29% ± 8% | |
capillary endothelial cell | 10 studies | 22% ± 6% | |
vein endothelial cell | 9 studies | 18% ± 4% | |
alveolar macrophage | 8 studies | 54% ± 16% | |
conventional dendritic cell | 8 studies | 29% ± 14% | |
epithelial cell | 7 studies | 32% ± 10% | |
epithelial cell of proximal tubule | 6 studies | 29% ± 6% | |
mesothelial cell | 6 studies | 32% ± 15% | |
astrocyte | 6 studies | 24% ± 11% | |
endothelial cell of vascular tree | 6 studies | 24% ± 6% | |
mononuclear phagocyte | 5 studies | 36% ± 15% | |
endothelial cell of sinusoid | 5 studies | 47% ± 23% | |
kidney loop of Henle epithelial cell | 5 studies | 25% ± 9% | |
microglial cell | 5 studies | 27% ± 11% | |
adipocyte | 5 studies | 23% ± 9% | |
leukocyte | 5 studies | 23% ± 5% | |
abnormal cell | 4 studies | 29% ± 11% | |
adventitial cell | 4 studies | 47% ± 13% | |
melanocyte | 4 studies | 34% ± 17% | |
erythrocyte | 4 studies | 40% ± 10% | |
glomerular endothelial cell | 3 studies | 25% ± 6% | |
podocyte | 3 studies | 42% ± 2% | |
extravillous trophoblast | 3 studies | 84% ± 3% | |
placental villous trophoblast | 3 studies | 96% ± 3% | |
tissue-resident macrophage | 3 studies | 57% ± 8% | |
Mueller cell | 3 studies | 23% ± 1% | |
intermediate monocyte | 3 studies | 38% ± 17% | |
dendritic cell | 3 studies | 46% ± 17% | |
GABAergic neuron | 3 studies | 29% ± 9% | |
glutamatergic neuron | 3 studies | 34% ± 14% | |
oligodendrocyte | 3 studies | 24% ± 5% | |
glial cell | 3 studies | 21% ± 4% | |
hepatocyte | 3 studies | 40% ± 17% | |
basal cell | 3 studies | 23% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 13 studies | 27% ± 13% | |
kidney | 6 studies | 24% ± 8% | |
uterus | 6 studies | 29% ± 4% | |
brain | 6 studies | 28% ± 10% | |
liver | 5 studies | 31% ± 17% | |
eye | 4 studies | 27% ± 12% | |
placenta | 3 studies | 83% ± 5% | |
ovary | 3 studies | 25% ± 2% | |
adipose | 3 studies | 25% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 5735.38 | 652 / 653 | 100% | 62.29 | 604 / 605 |
kidney | 100% | 7620.47 | 89 / 89 | 100% | 118.18 | 897 / 901 |
prostate | 100% | 3947.35 | 244 / 245 | 99% | 53.31 | 495 / 502 |
liver | 99% | 6895.65 | 223 / 226 | 100% | 66.14 | 404 / 406 |
breast | 100% | 8058.22 | 459 / 459 | 98% | 58.89 | 1097 / 1118 |
adrenal gland | 100% | 6163.94 | 257 / 258 | 97% | 73.34 | 223 / 230 |
ovary | 100% | 7087.01 | 180 / 180 | 97% | 46.15 | 415 / 430 |
lung | 100% | 11637.94 | 577 / 578 | 96% | 78.98 | 1114 / 1155 |
brain | 94% | 2700.91 | 2491 / 2642 | 100% | 63.35 | 705 / 705 |
uterus | 99% | 6964.15 | 169 / 170 | 93% | 59.59 | 427 / 459 |
bladder | 100% | 9625.05 | 21 / 21 | 90% | 69.72 | 455 / 504 |
pancreas | 93% | 2515.47 | 304 / 328 | 97% | 72.31 | 172 / 178 |
skin | 89% | 8877.57 | 1605 / 1809 | 100% | 193.71 | 470 / 472 |
intestine | 100% | 6500.70 | 963 / 966 | 79% | 35.45 | 415 / 527 |
stomach | 89% | 4453.02 | 319 / 359 | 82% | 35.00 | 234 / 286 |
esophagus | 84% | 4293.17 | 1218 / 1445 | 78% | 32.31 | 143 / 183 |
adipose | 100% | 12978.14 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 164.86 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 130.35 | 29 / 29 |
spleen | 100% | 8833.61 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6792.50 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 98% | 3062.52 | 785 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 5524.50 | 836 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 76% | 35.93 | 34 / 45 |
peripheral blood | 29% | 1090.85 | 270 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0034230 | Biological process | enkephalin processing |
GO_0016540 | Biological process | protein autoprocessing |
GO_0043373 | Biological process | CD4-positive, alpha-beta T cell lineage commitment |
GO_0097067 | Biological process | cellular response to thyroid hormone stimulus |
GO_0030574 | Biological process | collagen catabolic process |
GO_0039654 | Biological process | fusion of virus membrane with host endosome membrane |
GO_0031638 | Biological process | zymogen activation |
GO_0048002 | Biological process | antigen processing and presentation of peptide antigen |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0071888 | Biological process | macrophage apoptotic process |
GO_0019064 | Biological process | fusion of virus membrane with host plasma membrane |
GO_0006508 | Biological process | proteolysis |
GO_0019065 | Biological process | receptor-mediated endocytosis of virus by host cell |
GO_0010952 | Biological process | positive regulation of peptidase activity |
GO_0060309 | Biological process | elastin catabolic process |
GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
GO_0019882 | Biological process | antigen processing and presentation |
GO_0051603 | Biological process | proteolysis involved in protein catabolic process |
GO_2001235 | Biological process | positive regulation of apoptotic signaling pathway |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0071682 | Cellular component | endocytic vesicle lumen |
GO_0005764 | Cellular component | lysosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0042583 | Cellular component | chromaffin granule |
GO_0005771 | Cellular component | multivesicular body |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0036021 | Cellular component | endolysosome lumen |
GO_0005634 | Cellular component | nucleus |
GO_0042393 | Molecular function | histone binding |
GO_0008656 | Molecular function | cysteine-type endopeptidase activator activity involved in apoptotic process |
GO_0097655 | Molecular function | serpin family protein binding |
GO_0001968 | Molecular function | fibronectin binding |
GO_0043394 | Molecular function | proteoglycan binding |
GO_0008234 | Molecular function | cysteine-type peptidase activity |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005518 | Molecular function | collagen binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CTSL |
Protein name | Cathepsin L Cathepsin L, isoform CRA_b Procathepsin L (EC 3.4.22.15) (Cathepsin L1) (Major excreted protein) (MEP) [Cleaved into: Cathepsin L; Cathepsin L heavy chain; Cathepsin L light chain] |
Synonyms | hCG_30369 CTSL1 |
Description | FUNCTION: Thiol protease important for the overall degradation of proteins in lysosomes (Probable). Plays a critical for normal cellular functions such as general protein turnover, antigen processing and bone remodeling. Involved in the solubilization of cross-linked TG/thyroglobulin and in the subsequent release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen (By similarity). In neuroendocrine chromaffin cells secretory vesicles, catalyzes the prohormone proenkephalin processing to the active enkephalin peptide neurotransmitter (By similarity). In thymus, regulates CD4(+) T cell positive selection by generating the major histocompatibility complex class II (MHCII) bound peptide ligands presented by cortical thymic epithelial cells. Also mediates invariant chain processing in cortical thymic epithelial cells (By similarity). Major elastin-degrading enzyme at neutral pH. Accumulates as a mature and active enzyme in the extracellular space of antigen presenting cells (APCs) to regulate degradation of the extracellular matrix in the course of inflammation (By similarity). Secreted form generates endostatin from COL18A1 . Critical for cardiac morphology and function. Plays an important role in hair follicle morphogenesis and cycling, as well as epidermal differentiation (By similarity). Required for maximal stimulation of steroidogenesis by TIMP1 (By similarity). .; FUNCTION: (Microbial infection) In cells lacking TMPRSS2 expression, facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via a slow acid-activated route with the proteolysis of coronavirus spike (S) glycoproteins in lysosome for entry into host cell . Proteolysis within lysosomes is sufficient to activate membrane fusion by coronaviruses SARS-CoV and EMC (HCoV-EMC) S as well as Zaire ebolavirus glycoproteins . .; FUNCTION: [Isoform 2]: Functions in the regulation of cell cycle progression through proteolytic processing of the CUX1 transcription factor . Translation initiation at downstream start sites allows the synthesis of isoforms that are devoid of a signal peptide and localize to the nucleus where they cleave the CUX1 transcription factor and modify its DNA binding properties . . |
Accessions | ENST00000678442.1 [P07711-1] A0A7I2V2H7 A0A7I2V5M3 A0A7I2YQB5 ENST00000677523.1 ENST00000677638.1 ENST00000676480.1 [P07711-1] ENST00000676531.1 [P07711-1] ENST00000678596.1 ENST00000677864.1 [P07711-3] ENST00000677955.1 A0A7I2V484 ENST00000678367.1 ENST00000677761.1 [P07711-1] A0A7I2V5F7 A0A7I2YQA2 ENST00000677019.1 [P07711-3] ENST00000678259.1 ENST00000340342.11 [P07711-1] P07711 ENST00000679149.1 [P07711-1] A0A7I2V601 ENST00000676946.1 [P07711-1] Q9HBQ7 ENST00000342020.6 ENST00000677821.1 [P07711-1] ENST00000679157.1 [P07711-1] ENST00000679025.1 ENST00000676881.1 [P07711-1] ENST00000679028.1 Q5T8F0 ENST00000677262.1 [P07711-1] ENST00000678649.1 ENST00000676769.1 [P07711-3] ENST00000343150.10 [P07711-1] ENST00000679030.1 ENST00000678599.1 |